Handelsavisen
prelaunch
Companies Basic Materials BIOO.NS
BI
BIOO.NS NSE (India) Specialty Chemicals

Biopol Chemicals Limited

$128,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
13,2 %
ROE
32,1 %
Net margin
8,8 %
Debt / equity
0,57
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

BIOO.NS is a specialty chemicals company that produces and sells chemical products, primarily generating revenue through the sale of these products to industrial and commercial customers.

Business. BIOO.NS is an Indian specialty chemicals company listed on the National Stock Exchange of India. The firm operates within the broader chemicals industry, focusing on the production and sale of chemical products. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the specialty chemicals sector.

Classification92 %
SectorBasic Materials
Business sectorChemicals
IndustrySpecialty Chemicals
ActivityChemicals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
32,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning BIOO.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials · THIS SECTOR+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to BIOO.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    BIOO.NS is an Indian specialty chemicals company listed on the National Stock Exchange of India. The firm operates within the broader chemicals industry, focusing on the production and sale of chemical products. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the specialty chemicals sector.

    Classification92 %
    SectorBasic Materials
    Business sectorChemicals
    IndustrySpecialty Chemicals
    ActivityChemicals
    AI synthesis
    GENERATED

    BIOO.NS has a debt-to-equity ratio of 0.57, indicating a moderate level of leverage, and a current ratio of 1.81, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company reported negative operating cash flow of -23,367,000 INR, which raises concerns about its ability to fund operations from core business activities. The free cash flow of 43,899,000 INR is positive, but the negative net cash position after subtracting total debt indicates potential liquidity constraints.

    In terms of profitability, BIOO.NS has a return on equity (ROE) of 32.07% and a return on assets (ROA) of 13.8%, both of which are strong indicators of efficient use of equity and assets. These figures suggest the company is generating substantial returns relative to its equity and asset base. The operating income of 64,629,000 INR and net income of 43,434,000 INR further support the company's profitability.

    The company's revenue is concentrated in a single business segment, as no specific segments are disclosed in the available data. There is no detailed geographic breakdown of revenue, but the company operates primarily in India, as indicated by the use of INR as the reporting currency. This lack of diversification may expose the company to regional economic and regulatory risks.

    The company's growth trajectory is not clearly defined in the available data, as there are no forward-looking revenue projections or historical growth rates provided. The capital expenditure of -245,000 INR suggests minimal investment in new assets, which may limit future growth potential. The absence of detailed outlook data makes it difficult to assess the company's future performance with certainty.

    The risk assessment indicates a medium level of liquidity risk and a low level of dilution risk. The key flag of negative net cash after subtracting total debt highlights a potential liquidity issue. The company has not disclosed any dilutive events in the near term, and the dilution risk is assessed as low. The company's financial structure and the absence of significant dilutive events suggest a relatively stable capital structure.

    There are no recent events or filings mentioned in the available data that would significantly impact the company's operations or financial position. The lack of recent disclosures or transcripts means that there is no additional information to consider regarding the company's strategic direction or operational performance.

    Key takeaways
    • BIOO.NS has a strong return on equity (32.07%) and return on assets (13.8%), indicating efficient use of equity and assets.
    • The company has a moderate debt-to-equity ratio of 0.57 and a current ratio of 1.81, suggesting a balanced capital structure.
    • The negative operating cash flow of -23,367,000 INR raises concerns about the company's ability to fund operations from core business activities.
    • The company's revenue is concentrated in a single business segment, with no detailed geographic breakdown provided.
    • The company has a low dilution risk and no significant dilutive events disclosed in the near term.
    • The lack of recent events or filings means there is no additional information to consider regarding the company's strategic direction or operational performance.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $128,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $135.4M
    Net cash
    -$76.9M
    Current ratio
    1.8
    Debt / equity
    0.6
    ROA
    13.8%
    ROE
    32.1%
    Cash conversion
    -54.0%
    CapEx / revenue
    -0.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin13,2 %Above P75
    Net Margin8,8 %Above median
    ROE32,1 %Best in class
    Capex / Rev-0,1 %Above P75
    D/E0,57Below median
    Cash Conv-0,54Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • BIOO.NS Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    BIOO.NSCanonical
    NSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage